- Home
- ATER vs IMRN Comparison
ATER vs IMRN Comparison
Compare ATER & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATER
- IMRN
- Stock Information
- Founded
- ATER 2014
- IMRN 1994
- Country
- ATER United States
- IMRN Australia
- Employees
- ATER N/A
- IMRN N/A
- Industry
- ATER Home Furnishings
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ATER Consumer Discretionary
- IMRN Health Care
- Exchange
- ATER Nasdaq
- IMRN Nasdaq
- Market Cap
- ATER 10.3M
- IMRN 9.2M
- IPO Year
- ATER N/A
- IMRN N/A
- Fundamental
- Price
- ATER $1.02
- IMRN $2.34
- Analyst Decision
- ATER
- IMRN
- Analyst Count
- ATER 0
- IMRN 0
- Target Price
- ATER N/A
- IMRN N/A
- AVG Volume (30 Days)
- ATER 126.5K
- IMRN 89.5K
- Earning Date
- ATER 11-10-2025
- IMRN 08-29-2025
- Dividend Yield
- ATER N/A
- IMRN N/A
- EPS Growth
- ATER N/A
- IMRN N/A
- EPS
- ATER N/A
- IMRN N/A
- Revenue
- ATER $85,668,000.00
- IMRN $4,777,422.00
- Revenue This Year
- ATER N/A
- IMRN N/A
- Revenue Next Year
- ATER $7.48
- IMRN N/A
- P/E Ratio
- ATER N/A
- IMRN N/A
- Revenue Growth
- ATER N/A
- IMRN 48.63
- 52 Week Low
- ATER $0.90
- IMRN $1.50
- 52 Week High
- ATER $3.50
- IMRN $2.48
- Technical
- Relative Strength Index (RSI)
- ATER 43.21
- IMRN 71.71
- Support Level
- ATER $0.99
- IMRN $2.12
- Resistance Level
- ATER $1.12
- IMRN $2.38
- Average True Range (ATR)
- ATER 0.08
- IMRN 0.14
- MACD
- ATER -0.01
- IMRN 0.01
- Stochastic Oscillator
- ATER 8.29
- IMRN 84.31
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.